{"pmid":32447721,"title":"Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.","text":["Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations.","BACKGROUND: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. AIMS: In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. METHODS: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. CONCLUSIONS: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.","Hepatol Int","Lau, George","Sharma, Manoj","32447721"],"abstract":["BACKGROUND: Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide. AIMS: In order to enhance scientific information interflow in the arena of liver diseases in Asia-Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials. METHODS: A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia-Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials. CONCLUSIONS: This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal."],"journal":"Hepatol Int","authors":["Lau, George","Sharma, Manoj"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447721","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s12072-020-10054-w","keywords":["aclf","apasl","cld","covid-19","ddlt","guidance","hepatology","immunosuppression","ldlt","liver injury"],"locations":["APASL","APASL"],"topics":["Prevention"],"weight":1,"_version_":1667698385972363264,"score":9.490897,"similar":[{"pmid":32298473,"title":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.","text":["Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.","Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and healthcare providers.","Hepatology","Fix, Oren K","Hameed, Bilal","Fontana, Robert J","Kwok, Ryan M","McGuire, Brendan M","Mulligan, David C","Pratt, Daniel S","Russo, Mark W","Schilsky, Michael L","Verna, Elizabeth C","Loomba, Rohit","Cohen, David E","Bezerra, Jorge A","Reddy, K Rajender","Chung, Raymond T","32298473"],"abstract":["Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and healthcare providers."],"journal":"Hepatology","authors":["Fix, Oren K","Hameed, Bilal","Fontana, Robert J","Kwok, Ryan M","McGuire, Brendan M","Mulligan, David C","Pratt, Daniel S","Russo, Mark W","Schilsky, Michael L","Verna, Elizabeth C","Loomba, Rohit","Cohen, David E","Bezerra, Jorge A","Reddy, K Rajender","Chung, Raymond T"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298473","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hep.31281","keywords":["sars-cov-2","cirrhosis","coronavirus","immunosuppression","transplantation"],"topics":["Prevention"],"weight":1,"_version_":1666138493195124736,"score":342.22165},{"pmid":32349198,"title":"Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic.","text":["Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic.","In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation.","Singapore Med J","Chang, Jason Pik Eu","Wong, Yu Jun","Yang, Wei Lyn","Lim, Kieron Boon Leng","Tan, Poh Seng","Ho, Gim Hin","Yip, Benjamin Cherng Hann","Li, James Weiquan","Chong, Chern Hao","Ong, David Eng Hui","Chua, Tju Siang","Vu, Charles Kien Fong","Gwee, Kok Ann","Ang, Tiing Leong","Tan, Chee Kiat","32349198"],"abstract":["In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation."],"journal":"Singapore Med J","authors":["Chang, Jason Pik Eu","Wong, Yu Jun","Yang, Wei Lyn","Lim, Kieron Boon Leng","Tan, Poh Seng","Ho, Gim Hin","Yip, Benjamin Cherng Hann","Li, James Weiquan","Chong, Chern Hao","Ong, David Eng Hui","Chua, Tju Siang","Vu, Charles Kien Fong","Gwee, Kok Ann","Ang, Tiing Leong","Tan, Chee Kiat"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349198","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.11622/smedj.2020069","keywords":["covid-19","sars-cov2","hepatology"],"locations":["Singapore","Singapore"],"countries":["Singapore"],"countries_codes":["SGP|Singapore"],"topics":["Prevention"],"weight":1,"_version_":1666138494974558210,"score":291.55142},{"pmid":32275784,"title":"Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?","text":["Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?","Evidence strongly supports that access to specialty gastroenterology or hepatology care in cirrhosis is associated with higher adherence to guideline-recommended care and improves clinical outcomes. Presently, only about one half of acute care hospitalizations for cirrhosis-related complications result in inpatient specialty care and the current hepatology workforce cannot meet the demand of patients with liver disease nationwide, particularly in less densely populated areas and in community-based practices not affiliated with academic centers. Telemedicine, defined as the delivery of health care services at a distance using electronic means for diagnosis and treatment, holds tremendous promise to increase access to broadly specialty care. The technology is cheap and easy to use, however, is presently limited in scale by interstate licensing restrictions and reimbursement barriers. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) has, in the short-term, accelerated the growth of telemedicine delivery as a public health and social distancing measure. Herein, we examine whether this public health crisis can accelerate the national conversation about broader adoption of telemedicine for routine medical care in non-crisis situations using a case series from our telehepatology program as a pragmatic example.","Hepatology","Serper, Marina","Cubell, Allen W","Deleener, Mary Elisabeth","Casher, Tara K","Rosenberg, Dale J","Whitebloom, Dale","Rosin, Roy M","32275784"],"abstract":["Evidence strongly supports that access to specialty gastroenterology or hepatology care in cirrhosis is associated with higher adherence to guideline-recommended care and improves clinical outcomes. Presently, only about one half of acute care hospitalizations for cirrhosis-related complications result in inpatient specialty care and the current hepatology workforce cannot meet the demand of patients with liver disease nationwide, particularly in less densely populated areas and in community-based practices not affiliated with academic centers. Telemedicine, defined as the delivery of health care services at a distance using electronic means for diagnosis and treatment, holds tremendous promise to increase access to broadly specialty care. The technology is cheap and easy to use, however, is presently limited in scale by interstate licensing restrictions and reimbursement barriers. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) has, in the short-term, accelerated the growth of telemedicine delivery as a public health and social distancing measure. Herein, we examine whether this public health crisis can accelerate the national conversation about broader adoption of telemedicine for routine medical care in non-crisis situations using a case series from our telehepatology program as a pragmatic example."],"journal":"Hepatology","authors":["Serper, Marina","Cubell, Allen W","Deleener, Mary Elisabeth","Casher, Tara K","Rosenberg, Dale J","Whitebloom, Dale","Rosin, Roy M"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275784","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/hep.31276","keywords":["connected health","hepatology","mhealth","telehealth","telehepatology"],"topics":["Prevention"],"weight":1,"_version_":1666138491694612481,"score":275.54712},{"pmid":32360055,"pmcid":"PMC7174166","title":"Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic.","text":["Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic.","This document, written by the French Association for the Study of the Liver (AFEF) board, aims to provide information to physicians involved in the care of patients with liver disease during the Coronavirus disease (COVID-19) epidemic. These are not based on a systematic review of the literature and a rigorous evaluation using the GRADE method. These are recommendations based on feedback from China available in the form of original articles or letters - for which the scientific evidence is often modest - and the rules put forward by American (1) and European (Boettler et al, 2020) hepatology societies, the French National Digestive Cancer Thesaurus (Di Fiore et al., 2020) and the Francophone Transplantation Society (4). These suggestions require adjustment according to the geographical particularities of the epidemic, available standard procedures and access to local resources. This document will be updated as regularly as possible according to the evolution of our knowledge and characteristics on the epidemic.","Clin Res Hepatol Gastroenterol","Ganne-Carrie, Nathalie","Fontaine, Helene","Dumortier, Jerome","Boursier, Jerome","Bureau, Christophe","Leroy, Vincent","Bourliere, Marc","32360055"],"abstract":["This document, written by the French Association for the Study of the Liver (AFEF) board, aims to provide information to physicians involved in the care of patients with liver disease during the Coronavirus disease (COVID-19) epidemic. These are not based on a systematic review of the literature and a rigorous evaluation using the GRADE method. These are recommendations based on feedback from China available in the form of original articles or letters - for which the scientific evidence is often modest - and the rules put forward by American (1) and European (Boettler et al, 2020) hepatology societies, the French National Digestive Cancer Thesaurus (Di Fiore et al., 2020) and the Francophone Transplantation Society (4). These suggestions require adjustment according to the geographical particularities of the epidemic, available standard procedures and access to local resources. This document will be updated as regularly as possible according to the evolution of our knowledge and characteristics on the epidemic."],"journal":"Clin Res Hepatol Gastroenterol","authors":["Ganne-Carrie, Nathalie","Fontaine, Helene","Dumortier, Jerome","Boursier, Jerome","Bureau, Christophe","Leroy, Vincent","Bourliere, Marc"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360055","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.clinre.2020.04.001","keywords":["covid-19","cholangiocytes","chronic liver disease","sars-cov-2"],"locations":["China","American"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138495917228033,"score":269.75824},{"pmid":32425991,"pmcid":"PMC7233236","title":"The liver in times of COVID-19: What hepatologists should know.","text":["The liver in times of COVID-19: What hepatologists should know.","The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding to the how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations to be considered in liver transplant patients or those having hepatocellular carcinoma or are under immunosuppressive therapy are being matter of analysis as information is being generated. Different treatments for COVID-19 are currently under study some of which may be associated to hepatotoxicity. In the present review we discuss current data on the COVID-19 and liver aiming to provide hepatologists with updated information to face this pandemic.","Ann Hepatol","Ridruejo, Ezequiel","Soza, Alejandro","32425991"],"abstract":["The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding to the how the infection affects the liver and relevance of pre-existing liver disease as a risk factor for acquiring the infection or having a severe disease are still scarce. Also, considerations to be considered in liver transplant patients or those having hepatocellular carcinoma or are under immunosuppressive therapy are being matter of analysis as information is being generated. Different treatments for COVID-19 are currently under study some of which may be associated to hepatotoxicity. In the present review we discuss current data on the COVID-19 and liver aiming to provide hepatologists with updated information to face this pandemic."],"journal":"Ann Hepatol","authors":["Ridruejo, Ezequiel","Soza, Alejandro"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425991","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.aohep.2020.05.001","keywords":["ace2, angiotensin-converting enzyme 2","alt, alanine aminotransferase","ards, acute respiratory distress syndrome","ast, aspartate aminotransferase","cdc, centers for disease control and prevention","covid-19, coronavirus disease 2019","evd, ebola virus disease","hbv, hepatitis b virus","hcc, hepatocellular carcinoma","icu, intensive care unit","il, interleukin","ilca, international liver cancer association","mafld, metabolic associated fatty liver diseases","nafld, non-alcoholic fatty liver disease","niddk, national institute of diabetes and digestive and kidney diseases","rdrp, rna-dependent rna polymerase","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus 2","tnf-alpha, tumor necrosis factor-alpha","who, world health organization","coronavirus","immunosuppression","liver disease","nsp, non-structural proteins","transplantation, cirrhosis"],"topics":["Treatment"],"weight":1,"_version_":1667352728923275264,"score":260.39804}]}